HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 11, November 2017 – Paediatric Illnesses       » Breakthrough new rice variety announced in Northern China       » Ebola vaccine approved in China       » Study reveals anti-cancer properties of a fungus used in traditional medicine       » Chinese scientists create genetically modified low-fat pigs       » China, Brazil and Russia are riskiest markets for compliance and regulation       » Why are Korean eggs salmonella-free?      
BIOBOARD - EUROPE
CAVATAK TM bladder cancer – positive preliminary data
Viralytics Limited has received positive preliminary data in bladder cancer in its collaboration with Professor Hardev Pandha's research team at The University of Surrey in the United Kingdom.

Initial findings indicate the presence of widespread ICAM-1 on the surface of human bladder cancer tissues. Viralytics’ lead oncolytic virus CAVATAKTM is based on demonstrated performance in targeting ICAM-1 receptors on the surface of cancer cells.

CAVATAKTM binds to the ICAM-1 receptor and works its way into the cancer cells. Phase I trial results have shown that after injection of CAVATAKTM , a number of patients’ melanoma lesions appear to stabilize or reduce in size. There is also evidence of possible immune activation in patients with reductions in injected lesions.

Injected CAVATAKTM virus clears from circulation within about 48 hours with possible secondary viral replication. In other words the mild virus keeps on working in patients as it is designed to persist in targeting cancer cells.

“These findings are very encouraging in our quest to enter early phase clinical evaluation of CAVATAKT M for the treatment of patient with superficial bladder cancer. Novel therapeutic strategies are urgently needed in the indication as evidenced by the current worldwide shortage of a Bacille Calmette-Guerin (BCG), a common treatment for this condition,” said Professor Pandha.

 Professor Pandha is the Head of Oncology at The University of Surrey and is an internationally recognized researcher and opinion-leader in virotherapy. He has published extensively on the pre-clinical and clinical activity of oncolytic viruses.

 In the United States alone, it is estimated that in 2012 there will be about 70 000 new cases and 15 000 deaths from bladder cancer.

 Viralytics has since advanced to a Phase II melanoma study using intratumourally injected CAVATAKTM under an Investigational New Drug application allowed by the US Food and Drug Administration. In this study, 13 subjects have so far been dosed in the Phase II CAVATAKTM trial with three demonstrating immune-related Progression-Free Survival at six months.

Click here for the complete issue.

NEWS CRUNCH  
news Novogen becomes Kazia Therapeutics
news Transforming healthcare through innovation: addressing unmet healthcare needs in Asia Pacific
news 77% of healthcare leaders believe they need to be a digital business to succeed: Microsoft study
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Paediatric Illnesses
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy